FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited

The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8